JPRN-UMIN000031670
Recruiting
未知
A prospective cohort study of neoadjuvant chemotherapy using carboplatin and dose dense paclitaxel for locally advanced cervical cancer - CC-NAC
ConditionsCervical cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Cervical cancer
- Sponsor
- Hyogo Cancer Center
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Patients with previous radiation therapy. 2\. Any active double cancers. 3\. Patients with any serious complications. 4\. Patients with hypersensitivity to castor ail. 5\. Patients with hypersensitivity to alcohol. 6\. Carrier of HBV or HCV. 7\. Patients with active infection which needs antibiotics. 8\. Patients with interstitial pneumonia. 9\. Pregnant woman. 10\. Patients regard to be inadequate for entering this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Prospective cohort study of neoadjuvant chemotherapy using tri-weekly carboplatin and weekly paclitaxel for patients with locally advanced cervical cancercervical cancerJPRN-UMIN000024136Hyogo Cancer CEnter100
Completed
Not Applicable
Multicenter Prospective Study of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic CancerJPRN-UMIN000029147Yamaguchi Pancreatic / Biliary Disease Study Group50
Completed
Not Applicable
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24
Completed
Not Applicable
Prospective cohort study of neoadjuvant chemoradiotherapy using GEM and nabPTX for borderline resectable pancreatic cancerBorderline resectable pancreatic cancerJPRN-UMIN000018366Department of gastroenterological surgery, Yokohama city university graduate school of medicine100
Completed
Not Applicable
A prospective randomized study of adjuvant chemotherapy with navelbine and cisplatin in completely resected non small cell lung cancerISRCTN95053737Pierre Fabre Oncologie (France)840